Prognostic factors that correlate with poorer outcomes for patients with metastatic disease include poor performance status, shorter prostate-specific antigen (PSA) doubling time, higher Gleason score, pain at presentation, high tumor volume, and visceral metastasis [7]. This evidence concerns the gene KLK3 and metastatic neoplasm.